Argenx Surges 11.93% on $949M Sales as Trading Volume Jumps into Top 500 Stocks

On July 31, 2025, argenx (ARGX) surged 11.93% with a trading volume of $0.93 billion, a 174.09% increase from the previous day. The biopharma firm reported $949 million in Q2 global product net sales, driven by VYVGART’s expansion across three indications. Over 2,500 patients are now on VYVGART SC in CIDP, and the prefilled syringe format is expanding access in Germany and Japan. ARGX-119 advanced to a registrational study in CMS after positive Phase 1b data, with three key pipeline readouts expected by year-end.

Argenx’s Vision 2030 strategy aims to treat 50,000 patients globally by 2030, with VYVGART’s market penetration accelerating in MG and CIDP. The company is expanding its immunology pipeline, including efgartigimod trials in 15 autoimmune diseases and ARGX-119’s potential in ALS and SMA. R&D expenses rose to $328 million in Q2, reflecting investments in registrational studies and first-in-class candidates like empasiprubart for MMN and CIDP. Financially, the firm posted a $245 million profit (EPS: $4.02), a significant improvement from Q2 2024.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present. This outperformed the benchmark return of 29.18%, generating an excess return of 137.53%. The strategy’s success is attributed to its ability to capture momentum driven by high liquidity, as evidenced by the significant volume surges seen in stocks like VICI Properties and Eli Lilly. This strategy reflects a market trend where liquidity concentration is a key factor in driving stock prices, particularly over short-term horizons. The consistent high returns underscore the effectiveness of this approach within the current market environment, where rapid liquidity shifts can create substantial trading opportunities. However, it is important to note that this strategy relies heavily on market structure and dynamics, which can evolve over time, potentially impacting its future performance.